المؤلفون: Akiyama H; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhao R; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ostermann LB; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Li Z; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tcheng M; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Yazdani SJ; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Moayed A; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pryor ML 2nd; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Slngh S; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Baran N; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ayoub E; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nishida Y; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mak PY; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ruvolo VR; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Carter BZ; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Schimmer AD; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Andreeff M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ishizawa J; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. JIshizawa@mdanderson.org.

المصدر: Leukemia [Leukemia] 2024 Apr; Vol. 38 (4), pp. 926.

نوع المنشور: Published Erratum

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: PubMed not MEDLINE; MEDLINE

المؤلفون: Akiyama H; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhao R; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ostermann LB; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Li Z; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tcheng M; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Yazdani SJ; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Moayed A; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pryor ML 2nd; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Slngh S; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Baran N; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ayoub E; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nishida Y; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mak PY; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ruvolo VR; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Carter BZ; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Schimmer AD; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Andreeff M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ishizawa J; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. JIshizawa@mdanderson.org.

المصدر: Leukemia [Leukemia] 2024 Apr; Vol. 38 (4), pp. 729-740. Date of Electronic Publication: 2023 Dec 26.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

مواضيع طبية MeSH: Ferroptosis* , Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/metabolism, Humans ; Mitochondria/metabolism ; Lipids ; Peptide Hydrolases/metabolism

المؤلفون: Liu JYW; School of Nursing, The Hong Kong Polytechnic University, Hong Kong, China (Hong Kong).; Research Institute for Smart Ageing, The Hong Kong Polytechnic University, Hong Kong, China (Hong Kong)., Mak PY; School of Nursing, The Hong Kong Polytechnic University, Hong Kong, China (Hong Kong)., Chan K; School of Nursing, The Hong Kong Polytechnic University, Hong Kong, China (Hong Kong)., Cheung DSK; School of Nursing, The Hong Kong Polytechnic University, Hong Kong, China (Hong Kong).; Research Institute for Smart Ageing, The Hong Kong Polytechnic University, Hong Kong, China (Hong Kong)., Cheung K; School of Nursing, The Hong Kong Polytechnic University, Hong Kong, China (Hong Kong)., Fong KNK; Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong, China (Hong Kong)., Kor PPK; School of Nursing, The Hong Kong Polytechnic University, Hong Kong, China (Hong Kong)., Lai TKH; School of Nursing, The Hong Kong Polytechnic University, Hong Kong, China (Hong Kong)., Maximo T; School of Design, The Hong Kong Polytechnic University, Hong Kong, China (Hong Kong).

المصدر: JMIR medical education [JMIR Med Educ] 2024 Feb 15; Vol. 10, pp. e48566. Date of Electronic Publication: 2024 Feb 15.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: JMIR Publications Country of Publication: Canada NLM ID: 101684518 Publication Model: Electronic Cited Medium: Internet ISSN: 2369-3762 (Electronic) Linking ISSN: 23693762 NLM ISO Abbreviation: JMIR Med Educ Subsets: MEDLINE

مواضيع طبية MeSH: Cognitive Dysfunction* , Education, Nursing, Baccalaureate* , Students, Nursing*, Aged ; Humans ; Empathy ; Learning ; Problem-Based Learning

المؤلفون: Nishida Y; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Ishizawa J; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Ayoub E; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Montoya RH; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Ostermann LB; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Muftuoglu M; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Ruvolo VR; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Patsilevas T; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Scruggs DA; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Khazaei S; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Mak PY; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Tao W; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Carter BZ; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Boettcher S; Department of Medical Oncology and Haematology, University Hospital Zurich, University of Zurich, Zurich 8091, Switzerland.; Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, The Broad Institute, Boston, MA 02115, USA., Ebert BL; Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, The Broad Institute, Boston, MA 02115, USA., Daver NG; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Konopleva M; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.; Section of Leukemia Biology Research, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Seki T; Daiichi Sankyo Co. Ltd., Tokyo 103-8426, Japan., Kojima K; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.; Department of Hematology, Kochi University, Nankoku, Kochi 783-8505, Japan., Andreeff M; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

المصدر: Science advances [Sci Adv] 2023 Dec; Vol. 9 (48), pp. eadh1436. Date of Electronic Publication: 2023 Nov 29.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101653440 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2375-2548 (Electronic) Linking ISSN: 23752548 NLM ISO Abbreviation: Sci Adv Subsets: MEDLINE

مواضيع طبية MeSH: Tumor Suppressor Protein p53*/genetics , Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/genetics , Leukemia, Myeloid, Acute*/pathology, Humans ; Proto-Oncogene Proteins c-mdm2/genetics ; Proto-Oncogene Proteins c-mdm2/metabolism ; Cell Line, Tumor ; Apoptosis/genetics

المؤلفون: Carter BZ; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Mak PY; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Muftuoglu M; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Tao W; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Ke B; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Pei J; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Bedoy AD; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Ostermann LB; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Nishida Y; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Isgandarova S; Center for Infectious and Inflammatory Disease, Texas A&M University, Institute of Bioscience and Technology, Houston, TX., Sobieski M; Center for Translational Cancer Research, Texas A&M University, Institute of Bioscience and Technology, Houston, TX., Nguyen N; Center for Translational Cancer Research, Texas A&M University, Institute of Bioscience and Technology, Houston, TX., Powell RT; Center for Translational Cancer Research, Texas A&M University, Institute of Bioscience and Technology, Houston, TX., Martinez-Moczygemba M; Center for Infectious and Inflammatory Disease, Texas A&M University, Institute of Bioscience and Technology, Houston, TX., Stephan C; Center for Translational Cancer Research, Texas A&M University, Institute of Bioscience and Technology, Houston, TX., Basyal M; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Boettcher S; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland., Ebert BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Shpall EJ; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Wallner B; Samus Therapeutics Inc, Topsfield, MA., Morgan RA; Samus Therapeutics Inc, Topsfield, MA., Karras GI; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX.; Genetics and Epigenetics Graduate Program, The University of Texas MD Anderson Cancer Center, UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX., Moll UM; Department of Pathology, Stony Brook University, Stony Brook, NY., Andreeff M; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.

المصدر: Blood [Blood] 2023 Sep 21; Vol. 142 (12), pp. 1056-1070.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/therapeutic use , Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/genetics , Leukemia, Myeloid, Acute*/pathology, Humans ; Animals ; Mice ; Tumor Suppressor Protein p53/genetics ; Tumor Suppressor Protein p53/metabolism ; Proto-Oncogene Proteins c-bcl-2 ; Apoptosis ; Stem Cells/metabolism ; Cell Line, Tumor

المؤلفون: Carter BZ; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. bicarter@mdanderson.org., Mak PY; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Tao W; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Ostermann LB; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Mak DH; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Ke B; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Ordentlich P; Syndax, Waltham, MA., McGeehan GM; Syndax, Waltham, MA., Andreeff M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. mandreef@mdanderson.org.

المصدر: Haematologica [Haematologica] 2023 Sep 01; Vol. 108 (9), pp. 2513-2519. Date of Electronic Publication: 2023 Sep 01.

نوع المنشور: Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Letter

بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/genetics, Humans ; fms-Like Tyrosine Kinase 3/genetics ; Heterografts ; Mutation ; Nuclear Proteins/genetics ; Proto-Oncogene Proteins c-bcl-2/genetics ; Animals ; Mice

المؤلفون: Carter BZ; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. bicarter@mdanderson.org., Mak PY; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tao W; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ayoub E; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ostermann LB; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Huang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Boettcher S; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland., Nishida Y; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ruvolo V; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hughes PE; Oncology Research, Amgen Inc, Thousand Oaks, CA, USA., Morrow PK; Amgen Inc, Thousand Oaks, CA, USA., Haferlach T; MLL Munich Leukemia Laboratory, Munich, Germany., Kornblau S; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Muftuoglu M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Andreeff M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mandreef@mdanderson.org.

المصدر: Blood cancer journal [Blood Cancer J] 2023 May 17; Vol. 13 (1), pp. 80. Date of Electronic Publication: 2023 May 17.

نوع المنشور: Published Erratum

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: PubMed not MEDLINE; MEDLINE

المؤلفون: Carter BZ; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. bicarter@mdanderson.org., Mak PY; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tao W; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ayoub E; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ostermann LB; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Huang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Boettcher S; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland., Nishida Y; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ruvolo V; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hughes PE; Oncology Research, Amgen Inc, Thousand Oaks, CA, USA., Morrow PK; Amgen Inc, Thousand Oaks, CA, USA., Haferlach T; MLL Munich Leukemia Laboratory, Munich, Germany., Kornblau S; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Muftuoglu M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Andreeff M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mandreef@mdanderson.org.

المصدر: Blood cancer journal [Blood Cancer J] 2023 Apr 24; Vol. 13 (1), pp. 57. Date of Electronic Publication: 2023 Apr 24.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/genetics , Leukemia, Myeloid, Acute*/metabolism , Antineoplastic Agents*/therapeutic use, Animals ; Mice ; Myeloid Cell Leukemia Sequence 1 Protein ; bcl-2-Associated X Protein/metabolism ; bcl-2-Associated X Protein/pharmacology ; bcl-2-Associated X Protein/therapeutic use ; Apoptosis ; Cell Line, Tumor ; Proto-Oncogene Proteins c-bcl-2

المؤلفون: Carter BZ; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Mak PY; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tao W; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhang Q; Section of Leukemia Biological Research, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ruvolo V; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kuruvilla VM; Section of Leukemia Biological Research, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang X; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Mak DH; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Battula VL; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Konopleva M; Section of Leukemia Biological Research, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hughes PE; Oncology Research, Amgen Inc., Thousand Oaks, California., Chen X; Oncology Research, Amgen Inc., Thousand Oaks, California., Morrow PK; Amgen Inc., Thousand Oaks, California., Andreeff M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

المصدر: Molecular cancer therapeutics [Mol Cancer Ther] 2022 Jun 01; Vol. 21 (6), pp. 879-889.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Apoptosis Regulatory Proteins* , Biomimetic Materials*/pharmacology , Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/metabolism, Animals ; Apoptosis ; Bridged Bicyclo Compounds, Heterocyclic/pharmacology ; Cell Line, Tumor ; Humans ; Mice ; Myeloid Cell Leukemia Sequence 1 Protein/genetics ; Proto-Oncogene Proteins c-bcl-2 ; Stem Cells/metabolism ; bcl-2-Associated X Protein/metabolism ; bcl-2-Associated X Protein/pharmacology

المؤلفون: Post SM; Department of Leukemia. SPost@mdanderson.org., Ma H; Department of Leukemia; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston., Malaney P; Department of Leukemia., Zhang X; Department of Leukemia., Aitken MJL; Department of Leukemia., Mak PY; Department of Leukemia; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston., Ruvolo VR; Department of Leukemia; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston., Yasuhiro T; Ono Pharmaceutical Co. Ltd., Research Center of Oncology, Osaka., Kozaki R; Ono Pharmaceutical Co. Ltd., Research Center of Oncology, Osaka., Chan LE; Department of Leukemia., Ostermann LB; Department of Leukemia; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston., Konopleva M; Department of Leukemia., Carter BZ; Department of Leukemia; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston., DiNardo C; Department of Leukemia., Andreeff MD; Department of Leukemia; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston., Khoury JD; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston. JKhoury@mdanderson.org., Ruvolo PP; Department of Leukemia; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston. pruvolo@mdanderson.org.

المصدر: Haematologica [Haematologica] 2022 Jun 01; Vol. 107 (6), pp. 1311-1322. Date of Electronic Publication: 2022 Jun 01.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

مواضيع طبية MeSH: Drug Resistance, Neoplasm* , Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/genetics , Protein Kinase Inhibitors*/pharmacology , c-Mer Tyrosine Kinase*/antagonists & inhibitors, Animals ; Apoptosis ; Bridged Bicyclo Compounds, Heterocyclic/pharmacology ; Cell Line, Tumor ; Extracellular Signal-Regulated MAP Kinases/metabolism ; Humans ; Mice ; Myeloid Cell Leukemia Sequence 1 Protein/metabolism ; Proteomics ; Sulfonamides/pharmacology ; fms-Like Tyrosine Kinase 3/genetics